Dr. Masoud M. Azizad, MD

Dr. Azizad practices at Dignity Health - Northridge Hospital Medical Center in Northridge, California, part of CommonSpirit Health.

Dr. Azizad's NPI, 1033174826, was assigned on April 18, 2006. Dr. Azizad graduated from New York Medical College in 1999. Dr. Azizad holds California license A74207.

Dr. Azizad's primary practice is Dignity Health - Northridge Hospital Medical Center, at 18300 Roscoe Blvd, Northridge, CA 91325 in Los Angeles County. The practice phone is (818) 885-8500.

Dr. Azizad's primary practice is Dignity Health - Northridge Hospital Medical Center in Northridge, California, part of CommonSpirit Health. The medical group on file is Valley Vascular Partners. Dmand AI also links Dr. Azizad to 1 more hospital, 2 home health agencies, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Azizad practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Azizad's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Azizad is board certified in internal medicine by the American Board of Internal Medicine. Dr. Azizad is licensed in California.

Dmand AI lists acid reflux, acute gastroduodenitis, acute skin infection, aneurysm, anxiety, arthritis, asthma and atrial fibrillation and flutter among the conditions Dr. Azizad treats.

CMS data shows 3,318 Medicare services from Dr. Azizad across 23 procedure codes in 2024, for 318 Medicare patients. Medicare paid $203,134 for them. Every service was in an office.

CMS counts 318 Medicare patients who saw Dr. Azizad in 2024. The largest group is 65 to 74, with 125 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 41% are also on Medicaid. Their average risk score is 1.33, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Azizad's median patient age at 66, with 53% women.

In 2024, Dr. Azizad wrote 9,528 Medicare Part D claims for 403 patients. 79% of them were for generic drugs. CMS names the drug for 8,718 of them, across 173 drugs with 11 or more claims each, at $1,488,684 in total drug cost. In 2023, CMS named 8,149 claims across 172 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Azizad for performance year 2024, reported individually. Dr. Azizad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Azizad as offering telehealth.

Dmand AI links 7 papers to Dr. Azizad, published from 2021 to 2024. 2021 was the busiest year, with 3. The most frequent topics are COVID-19, Double-Blind Method and SARS-CoV-2. Dr. Azizad has published most often in N Engl J Med. Dr. Azizad's most frequent co-authors are Jose Francisco Cardona, MD, Chad Scott Crystal, MD and Elizabeth R. Duke, MD.

Dmand AI links Dr. Azizad to 8 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include COVID-19, Pneumonia, Viral and Alzheimer Disease. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Azizad that name 2 trials.

CMS Open Payments shows 1,340 general payments to Dr. Azizad from 59 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 88% of the total. Abbvie Inc. paid the most, $2,703. It also lists 8 research payments totaling $19,568 from 2018 to 2024, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Azizad, most recently CMS Stage 1 EHR in 2013.

Dr. Azizad graduated from New York Medical College in 1999.

Dr. Azizad is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.